We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Potential Biomarkers of AMD Identified in Human Plasma

By LabMedica International staff writers
Posted on 26 Sep 2017
Patients with even an early stage of age-related macular degeneration (AMD) carry signs of the disease in their blood that may be detected through special laboratory tests, according to a new study. More...
The findings may lead to earlier diagnoses, better prognostic information, and ultimately more precise treatments for earlier stages of AMD, the leading cause of blindness in people over age 50 in developed countries.

The study, led by researchers based at Massachusetts Eye and Ear Infirmary (Boston, MA, USA), a Harvard Medical School teaching hospital, found that applying metabolomics enabled identification of blood profiles associated with AMD and its level of severity.

“Because the signs and symptoms of early stage AMD are very subtle, with visual symptoms only becoming apparent at more advanced stages of the disease, identification of biomarkers in human blood plasma may allow us to better understand the early to intermediate stages of AMD so we may intervene sooner and ultimately provide better care,” said co-senior author Joan W. Miller, MD, of Mass. Eye and Ear and of Massachusetts General Hospital, and professor at Harvard Medical School.

The prevalence of AMD is expected to increase along with aging of the global population. While AMD has recognized genetic and lifestyle risk factors (including diet and smoking status), the field currently lacks reliable measures to identify patients who may be at high risk of developing AMD, including those who may progress to the advanced, blinding forms of the disease.

“The metabolome – the set of metabolites present in an individual – is thought to closely represent the true functional state of complex diseases. This is why we used it to test 90 blood samples obtained from study participants with all three stages of AMD (30 with early-stage disease, 30 with intermediate-stage, 30 with late-stage) and 30 samples from patients without AMD,” said first author Ines Lains, MD, research fellow at Mass. Eye and Ear. The metabolomics data analysis was performed in collaboration with Dr. Lasky-Su and colleagues at the Channing Division of Network Medicine of Brigham and Women’s Hospital (Boston, MA, USA).

Their approach revealed 87 metabolites in the blood that were significantly different between subjects with AMD and those without. Furthermore, the team noted varying characteristics between the blood profiles of each stage of disease. Of the 87 molecules associated with AMD, most belonged to lipid pathways, and 6 of the 7 most significant metabolites identified were lipids. Previous research has suggested that lipids may be involved in the development of AMD, although the exact role of lipids in the disease process remains unclear. The results from this study support this suggestion, as well as indicate that metabolomics profiling may provide novel insights into relationship between lipids and AMD.

“We believe this work will help launch the era of personalized medicine in treatment of AMD,” said co-senior author Deeba Husain, MD, of Mass. Eye and Ear and associate professor at Harvard Medical School, “and it gives us clues to differentiate the progressers from non-progressors. This research also gives us insight into important role of lipids in AMD, which will provide novel targets for treatment in the early stage of disease, thus preserving vision."

The study, by Laíns I et al, was published September 12, 2017, in the journal Ophthalmology.

Related Links:
Massachusetts Eye and Ear Infirmary


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
New
Rapid Test Reader
DIA5000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.